Trump's 200% tariff threat leaves pharma firms scrambling with scenario planning
-
最新报道：Former President Donald Trump has proposed imposing 200% tariffs on pharmaceutical imports, a move that could significantly increase drug prices and squeeze profit margins for U.S. pharmaceutical companies. Industry analysts warn the policy may disrupt supply chains and lead to higher costs for consumers, as many drugmakers rely on overseas manufacturing. The proposal has sparked concerns among healthcare providers and patient advocacy groups, who fear limited access to affordable medications. Pharmaceutical stocks dipped following the announcement, reflecting investor uncertainty over potential revenue impacts. The plan, if implemented, could reshape global trade dynamics in the sector.
下一篇
Polkadot Predicted to Grow 6% by 2030 Amid Steady Market Sentiment Qubetics Surges 1050% in First Hour Post-Launch
- Polkadot (DOT) is projected to grow 6% by 2030 amid steady market sentiment, according to ...
24小时热点
热点专题
407106